Essentially, GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring hormone in our bodies that plays a crucial role in regulating blood sugar levels and slowing down gastric emptying, which in turn contributes directly to that feeling of fullness and satiety
Barrier-First Healing: Unlike retinol, copper peptides are naturally anti-inflammatory
When a GLP-1 agonist binds its receptor, it can activate two downstream pathways: cAMP (G-protein) pathway: Mediates the metabolic benefits (insulin secretion, appetite suppression, glucose control) Beta-arrestin pathway: Triggers receptor internalization and desensitization, and may contribute to nausea and vomiting Drugs that preferentially activate the cAMP pathway while minimizing beta-arrestin recruitment -- called "biased agonists" -- may maintain efficacy while reducing GI side effects
The gastrointestinal tract in hunger and satiety signalling
Thats why GLP-1s show up in clinical trials for cardiovascular disease, kidney disease, heart failure, dementia, NASH (fatty liver), and cancer
Patients with commercial insurance covering Mounjaro for type 2 diabetes can access the medication for $25 monthly using the savings card